Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer

NCT ID: NCT00006486

Last Updated: 2013-01-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 335 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-10-31

Brief Summary

Randomized phase II trial to study the effectiveness of carboxyamidotriazole in treating patients who have metastatic kidney cancer. Carboxyamidotriazole may stop the growth of kidney cancer by stopping blood flow to the tumor

Detailed Description

OBJECTIVES:

I. Determine the toxicity and disease-stabilizing effect of carboxyamidotriazole in patients with metastatic renal cell carcinoma.

II. Determine the objective response rate in patients treated with this drug.

OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to time from diagnosis of metastatic disease to study entry (fewer than 24 months vs 24 months or more).

Patients receive oral carboxyamidotriazole (CAI) daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.

Patients with stable disease are randomized to one of two treatment arms.

Arm I: Patients receive oral CAI as above.

Arm II: Patients receive a placebo.

Treatment repeats every 4 weeks for at least 4 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression are unblinded and those on placebo begin oral CAI as above.

Patients are followed every 6 months.

PROJECTED ACCRUAL: A maximum of 335 patients will be accrued for this study within 15-25 months.

Conditions

Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Arm I (carboxyaminoimidazole)

Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.

Patients receive oral CAI as above.

Group Type: EXPERIMENTAL

carboxyamidotriazole

Intervention Type: DRUG

Given orally

Arm II (carboxyamidotriazole, placebo)

Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.

Patients receive a placebo.

Group Type: EXPERIMENTAL

carboxyamidotriazole

Intervention Type: DRUG

Given orally

placebo

Intervention Type: OTHER

Given orally

Interventions

carboxyamidotriazole

Given orally

Intervention Type: DRUG

placebo

Given orally

Intervention Type: OTHER

Other Intervention Names

CAI; carboxyamido-triazole; carboxyaminoimidazole; PLCB

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed renal cell carcinoma

• Metastatic or unresectable disease
• Documented disease progression, even after nephrectomy
• At least 1 unidimensionally measurable lesion

• At least 20 mm by conventional techniques
• At least 10 mm by spiral CT scan
• The following lesions are not considered measurable:

• Bone lesions
• Leptomeningeal disease
• Ascites
• Pleural/pericardial effusion
• Abdominal masses not confirmed and followed by imaging
• Cystic lesions
• Performance status - CTC 0-2
• WBC at least 2,000/mm^3
• Platelet count at least 75,000/mm^3
• Bilirubin no greater than upper limit of normal (ULN)
• AST no greater than 2.5 times ULN
• Creatinine no greater than 2.0 mg/dL
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No baseline neuropathy or cerebellar dysfunction greater than grade 1
• At least 4 weeks since prior immunotherapy
• No prior carboxyamidotriazole
• No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)
• Concurrent epoetin alfa allowed
• At least 4 weeks since prior chemotherapy
• No concurrent chemotherapy
• No concurrent hormonal therapy except steroids for adrenal failure or hormones for conditions not related to disease (e.g., insulin for diabetes)
• At least 4 weeks since prior radiotherapy
• No concurrent palliative radiotherapy
• See Disease Characteristics
• At least 4 weeks since prior surgery

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Walter Stadler

Role: PRINCIPAL_INVESTIGATOR

Cancer and Leukemia Group B

Locations

Cancer and Leukemia Group B

Chicago, Illinois, United States

Countries

United States

Other Identifiers

CLB-69901

Identifier Type: -

Identifier Source: secondary_id

U10CA031946

Identifier Type: NIH

Identifier Source: secondary_id

View Link

CDR0000068317

Identifier Type: REGISTRY

Identifier Source: secondary_id

NCI-2012-02364

Identifier Type: -

Identifier Source: org_study_id